Home
Resources
Publications
17α Hydroxyprogesterone Caproate for Prevention of Recurrent Spontaneous Preterm Birth

17α Hydroxyprogesterone Caproate for Prevention of Recurrent Spontaneous Preterm Birth

Paul Merlob, Bracha Stahl, Gil Klinger

Reprod Toxicol. 2012 Jan;33(1):15-9.

PMID: 22120850

Abstract:

Use of 17-alpha-hydroxyprogesterone caproate for the prevention of spontaneous preterm birth in women at risk is reviewed. Early studies regarding this topic reached contradicting conclusions, however recent studies showed that weekly injections of 17-alpha-hydroxyprogesterone caproate beginning at 16-20 weeks' gestation resulted in a substantial reduction in the rate of spontaneous recurrent preterm birth. Long-term follow-up of children exposed in-utero to the drug has shown normal growth and development and normal scores for gender specific roles. In conclusion, 17-alpha-hydroxyprogesterone caproate is currently the only drug with sufficient evidence to support its use for prevention of spontaneous recurrent preterm birth.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP68962-A	17α-Hydroxyprogesterone		68-96-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: